Print
06 July 2015
PitchBook Blog
As highlighted in our 2Q 2015 U.S. Venture Industry Report, the first quarter of the year proved the continuing strength of the U.S. venture capital market, particularly at the late stage ($8.3 billion of capital invested). European venture capital was no different, with €1.9 billion of its total €2.8 billion invested coming at the late stage, as covered in our 2Q 2015 European PE Breakdown.
As U.S. VC activity in Europe increases, it’s worth taking a look at some U.S.-based investors that have been the most involved in Europe’s late stage activity since 2013:
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.